Inside 'Project Black Walnut' that sheds light on how Google thinks about Apple's ad business
The newly surfaced report appears to have been assembled by Google strategists to try to imagine what kind of ad business ...
Fund Providers Flock to Vanguard’s ETF Share Class
Almost three dozen fund providers have requested approval from the SEC to use Vanguard’s previously patented ETF-as-a-share ...
Louise Erdrich recommends 5 books by Native and Indigenous authors
Her first novel, "Love Medicine," published in 1984, followed five Ojibwe families in North Dakota and Minnesota. She ...
Medscape1d
Semaglutide Rocketing Past Statins as Millions Eligible
A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.
Why is bitcoin's $100,000 push stalling? These long-term holders can't resist selling.
Bitcoin's push for the $100,000 threshold remained stalled Tuesday, with some investors appearing to book profits following the crypto's rally to a record high.
Canadian Dollar catches a break from selling pressure on Wednesday
The Canadian Dollar (CAD) caught a much-needed bid on Wednesday, clawing back a sliver of recently-lost ground after the ...
Dogecoin Price Forecast: Technical indicators show bearish divergence as holders book profits
The RSI shows a bearish divergence, and the MACD suggests a sell signal. The NPL indicator shows DOGE holders are booking ...
The Globe and Mail6d
Paul Waldie
He also wrote a best-selling book on the McCain family called A House Divided. Along with the Globe, Paul has also worked at the Vancouver Province, the Montreal Gazette, the Financial Post and ...
‘We are time’s subjects’: Author Clock keeps track of the hours, one literary quotation at a time
Chicago engineer Jose Cardona says the idea for a clock wasn’t his alone, he was just the first to build one. Four years ...
The Bookseller6d
Translation rights sales on the rise for university presses, despite roadblocks
Earlier this year, Edinburgh University Press (EUP) announced its new partnership with Andrew Nurnberg Associates ...
Verona Pharma: In COPD, There's A Corner With Their Name On It
Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market.